RxDoctor Payments Data

Morgan Solari

Family · Indianapolis, INNPI 1003562281

Payments from drug & device makers

$6,158in general payments, 2019–2025

Across 366 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$762
  • Axsome Therapeutics, Inc.$526
  • Medtronic$422
  • Pfizer$408
  • Lilly USA, LLC$377
  • Harmony Biosciences LLC$261
  • plus $3K from 43 others

What the payments were for

  • Travel & lodging$1442%
  • Food & beverage$5,97397%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,158 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$68,101
Medicare patients
112
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen817$27,702
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen796$23,622
Nurtec OdtRimegepant Sulfate13$17,276
BelbucaBuprenorphine Hcl25$16,455
HorizantGabapentin Enacarbil13$13,088
MovantikNaloxegol Oxalate25$10,957
OxycontinOxycodone Hcl24$8,024
Lidocaine50$7,040
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl30$5,907
Morphine Sulfate ErMorphine Sulfate152$5,353
Gabapentin379$4,939
Pregabalin183$4,833
Oxycodone Hcl189$4,340
Oxymorphone Hcl ErOxymorphone Hcl12$3,921
Buprenorphine13$3,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$408$17,27613 claims
Collegium Pharmaceutical, Inc.Belbuca$145$16,45525 claims
Redhill Biopharma Inc.Movantik$17$10,95725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →